Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: AIN457 6 mg/kg i.v.Drug: PlaceboDrug: AIN457 3 mg/kg
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 381
- Registration Number
- NCT04209205
- Locations
- πΉπ·
Novartis Investigative Site, Bursa, Gorukle, Turkey
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
- Conditions
- Advanced HER2+Breast Cancer
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04208178
- Locations
- πΊπΈ
Highlands Oncology Group, Fayetteville, Arkansas, United States
πΊπΈUniversity of California LA, Los Angeles, California, United States
πͺπΈNovartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 275
- Registration Number
- NCT04181762
- Locations
- πΊπΈ
University Of Alabama, Birmingham, Alabama, United States
πΊπΈKaiser Permanente Fontana, Fontana, California, United States
πΊπΈUniversity of California LA, Los Angeles, California, United States
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 703
- Registration Number
- NCT04179175
- Locations
- πΊπΈ
Northwest Arkansas Center, Rogers, Arkansas, United States
πΊπΈMedDerm Associates, San Diego, California, United States
πΊπΈUniversity Clinical Trials, San Diego, California, United States
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
- Conditions
- Spinal Muscular Atrophy (SMA)
- Interventions
- Other: Prospective observational registry
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 700
- Registration Number
- NCT04174157
- Locations
- π¬π·
Penteli Children's Hospital, Penteli, Attikis, Greece
π¬π·St. Sophia Children's Hospital, Thessaloniki, Greece
π―π΅Nikko Memorial Hospital, Hokkaido, Japan
Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT04164732
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 527
- Registration Number
- NCT04156620
- Locations
- πΉπ·
Novartis Investigative Site, Istanbul, Turkey
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: Tisagenlecleucel
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04156659
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT04154787
- Locations
- π¬π§
Novartis Investigative Site, Manchester, United Kingdom
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT04150029
- Locations
- πΊπΈ
25Uni of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈYale University School Of Medicine, New Haven, Connecticut, United States
πΊπΈUni Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States